Targeted inhibition of ERα signaling and PIP5K1α/Akt pathways in castration‐resistant prostate cancer

J. Semenas et al.

Molecular Oncology (2020)

Institution: Umeå University, Sweden

Cell Line: PC-3 (Human prostate adenocarcinoma cell line)

Research Area: Cancer research

Tags: HoloMonitor M4, Cell morphology, castration-resistant prostate cancer, estrogen receptor, PI3K/AKT pathway andtamoxifen, PIP5K1a, targeted therapy

Conclusions: As there are limited treatment options for metastatic prostate cancer (PCa), the disease progresses to castration-resistant after the initial androgen-deprivation therapy. Thus, there is a need to develop new treatment strategies to effectively treat patients. In this study, J. Semenas with colleagues have developed a novel selective inhibitor (ISA-2011B), which exhibits specific effects towards subgroups of PCas alone and in combination with tamoxifen and can provide new therapeutic opportunities. Authors have used HoloMonitor M4 to study PC-3 cell morphology changes after drug treatment.

Read the article …